Debanjana Chatterjee, an analyst from JonesTrading, reiterated the Buy rating on Theravance Biopharma. The associated price target is $42.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Debanjana Chatterjee’s rating is based on the promising potential of Theravance Biopharma’s drug, ampreloxetine, particularly in treating multiple system atrophy (MSA). The drug addresses a significant unmet need in managing neurogenic orthostatic hypotension (nOH), a condition that severely impacts patients’ quality of life. Unlike existing treatments, ampreloxetine offers the possibility of sustained symptom relief without the risk of supine hypertension, which could greatly improve patient independence and overall well-being.
Furthermore, the upcoming Phase 3 CYPRESS trial is strategically designed to replicate positive results from previous studies, enhancing the likelihood of success. The alignment with the FDA on trial design reduces regulatory risks, and the concentrated MSA market allows for an efficient launch strategy. The strong intent to prescribe among specialists and favorable payer surveys suggest a rapid market uptake post-approval, positioning ampreloxetine as a potential standard of care in MSA treatment.
Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, KalVista Pharmaceuticals, and EyePoint Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 39.1% and a 69.81% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.